Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Neuropathological correlates of amyloid PET imaging in Down syndrome.

Abrahamson EE, Head E, Lott IT, Handen BL, Mufson EJ, Christian BT, Klunk WE, Ikonomovic MD.

Dev Neurobiol. 2019 Aug 4. doi: 10.1002/dneu.22713. [Epub ahead of print] Review.

PMID:
31379087
2.

Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure.

Mattos MK, Sereika SM, Beach SR, Kim H, Klunk WE, Knox M, Nadkarni NK, Parker LS, Roberts JS, Schulz R, Tamres L, Lingler JH.

J Alzheimers Dis. 2019 Jul 17. doi: 10.3233/JAD-190091. [Epub ahead of print]

PMID:
31322563
3.

Association between Brain Amyloid, White Matter Hyperintensities and Hypometabolism, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.

Nadkarni NK, Tudorascu D, Campbell E, Snitz BE, Cohen AD, Halligan E, Mathis CA, Aizenstein HJ, Klunk WE.

J Gerontol A Biol Sci Med Sci. 2019 Apr 8. pii: glz088. doi: 10.1093/gerona/glz088. [Epub ahead of print]

PMID:
30957843
4.

Leisure Activity, Brain β-amyloid, and Episodic Memory in Adults with Down Syndrome.

Mihaila I, Handen BL, Christian BT, Lao PJ, Cody KA, Klunk WE, Tudorascu DL, Cohen AD, Okonkwo OC, Hartley SL.

Dev Neurobiol. 2019 Mar 26. doi: 10.1002/dneu.22677. [Epub ahead of print]

PMID:
30912871
5.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

6.

Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women.

Wu M, Thurston RC, Tudorascu DL, Karim HT, Mathis CA, Lopresti BJ, Kamboh MI, Cohen AD, Snitz BE, Klunk WE, Aizenstein HJ.

Neurobiol Aging. 2019 Apr;76:141-150. doi: 10.1016/j.neurobiolaging.2018.11.020. Epub 2018 Dec 1.

PMID:
30711677
7.

Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.

Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H.

Mol Cell Neurosci. 2019 Jun;97:3-17. doi: 10.1016/j.mcn.2018.12.004. Epub 2018 Dec 8. Review.

PMID:
30537535
8.

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.

Hu Z, Wang L, Ma S, Kirisci L, Feng Z, Xue Y, Klunk WE, Kamboh MI, Sweet RA, Becker J, Lv Q, Lopez OL, Xie XQ.

Alzheimers Dement (N Y). 2018 Oct 14;4:542-555. doi: 10.1016/j.trci.2018.09.001. eCollection 2018.

9.

Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.

Yan Q, Nho K, Del-Aguila JL, Wang X, Risacher SL, Fan KH, Snitz BE, Aizenstein HJ, Mathis CA, Lopez OL, Demirci FY, Feingold E, Klunk WE, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Cruchaga C, Kamboh MI.

Mol Psychiatry. 2018 Oct 25. doi: 10.1038/s41380-018-0246-7. [Epub ahead of print]

10.

Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Tudorascu DL, Anderson SJ, Minhas DS, Yu Z, Comer D, Lao P, Hartley S, Laymon CM, Snitz BE, Lopresti BJ, Johnson S, Price JC, Mathis CA, Aizenstein HJ, Klunk WE, Handen BL, Christian BT, Cohen AD.

Neurobiol Aging. 2019 Jan;73:171-176. doi: 10.1016/j.neurobiolaging.2018.09.030. Epub 2018 Sep 27.

PMID:
30359879
11.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

PMID:
30347188
12.

Distinct cytokine profiles in human brains resilient to Alzheimer's pathology.

Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, Parisi JE, Lowe VJ, Petersen RC, Kofler J, Ikonomovic MD, López O, Klunk WE, Mayeux RP, Frosch MP, Wood LB, Gomez-Isla T.

Neurobiol Dis. 2019 Jan;121:327-337. doi: 10.1016/j.nbd.2018.10.009. Epub 2018 Oct 15.

PMID:
30336198
13.

Sleep moderates the relationship between amyloid beta and memory recall.

Wilckens KA, Tudorascu DL, Snitz BE, Price JC, Aizenstein HJ, Lopez OL, Erickson KI, Lopresti BJ, Laymon CM, Minhas D, Mathis CA, Buysse DJ, Klunk WE, Cohen AD.

Neurobiol Aging. 2018 Nov;71:142-148. doi: 10.1016/j.neurobiolaging.2018.07.011. Epub 2018 Jul 26.

PMID:
30138767
14.

Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma.

Groot C, Tolboom N, Ikonomovic MD, Lammertsma AA, Boon BDC, Barkhof F, Scheltens P, Klunk WE, Rozemuller AJM, Ossenkoppele R, van Berckel BNM.

J Alzheimers Dis. 2018;65(1):71-77. doi: 10.3233/JAD-180316.

PMID:
30040724
15.

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Benzinger TLS.

Neuroimage Clin. 2018 Apr 25;19:406-416. doi: 10.1016/j.nicl.2018.04.022. eCollection 2018.

16.

Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load.

Minhas DS, Price JC, Laymon CM, Becker CR, Klunk WE, Tudorascu DL, Abrahamson EE, Hamilton RL, Kofler JK, Mathis CA, Lopez OL, Ikonomovic MD.

Neuroimage Clin. 2018 Apr 4;19:182-189. doi: 10.1016/j.nicl.2018.04.007. eCollection 2018.

17.

The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods.

Tudorascu DL, Minhas DS, Lao PJ, Betthauser TJ, Yu Z, Laymon CM, Lopresti BJ, Mathis CA, Klunk WE, Handen BL, Christian BT, Cohen AD.

Alzheimers Dement (Amst). 2018 Apr 21;10:332-339. doi: 10.1016/j.dadm.2018.03.006. eCollection 2018.

18.

Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale.

Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, Pontecorvo MJ, Mintun MA, Devous MD Sr.

Alzheimers Dement. 2018 Dec;14(12):1565-1571. doi: 10.1016/j.jalz.2018.06.1353. Epub 2018 Jul 11.

PMID:
30006100
19.

Molecular imaging: What is right and what is an illusion?

Klunk WE.

Alzheimers Dement (Amst). 2018 Feb 10;10:217-220. doi: 10.1016/j.dadm.2018.01.004. eCollection 2018.

20.

Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation.

Lao PJ, Handen BL, Betthauser TJ, Cody KA, Cohen AD, Tudorascu DL, Stone CK, Price JC, Johnson SC, Klunk WE, Christian BT.

Brain Imaging Behav. 2019 Apr;13(2):345-353. doi: 10.1007/s11682-018-9888-y.

21.

Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality.

Lopez OL, Becker JT, Chang Y, Klunk WE, Mathis C, Price J, Aizenstein HJ, Snitz B, Cohen AD, DeKosky ST, Ikonomovic M, Kamboh MI, Kuller LH.

Neurology. 2018 May 22;90(21):e1920-e1928. doi: 10.1212/WNL.0000000000005549. Epub 2018 Apr 25.

22.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
23.

Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Johnson SC, Klunk WE, Christian BT.

J Alzheimers Dis. 2018;61(2):631-644. doi: 10.3233/JAD-170720.

24.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

25.

Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.

Zhao Y, Tudorascu DL, Lopez OL, Cohen AD, Mathis CA, Aizenstein HJ, Price JC, Kuller LH, Kamboh MI, DeKosky ST, Klunk WE, Snitz BE.

JAMA Neurol. 2018 Jan 1;75(1):88-96. doi: 10.1001/jamaneurol.2017.3029.

26.

Small-molecule PET Tracers for Imaging Proteinopathies.

Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE.

Semin Nucl Med. 2017 Sep;47(5):553-575. doi: 10.1053/j.semnuclmed.2017.06.003. Epub 2017 Jul 13. Review.

27.

Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Hartley SL, Handen BL, Devenny D, Mihaila I, Hardison R, Lao PJ, Klunk WE, Bulova P, Johnson SC, Christian BT.

Neurobiol Aging. 2017 Oct;58:68-76. doi: 10.1016/j.neurobiolaging.2017.05.019. Epub 2017 Jun 2.

28.

Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Mailick MR, Klunk WE, Johnson SC, Christian BT.

Alzheimers Dement (Amst). 2017 May 23;9:1-9. doi: 10.1016/j.dadm.2017.05.001. eCollection 2017.

29.

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

Marquié M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Antón-Fernández A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M, Bien EA, Vanderburg CR, Costantino I, Makaretz S, DeVos SL, Oakley DH, Gomperts SN, Growdon JH, Domoto-Reilly K, Lucente D, Dickerson BC, Frosch MP, Hyman BT, Johnson KA, Gómez-Isla T.

Ann Neurol. 2017 Jan;81(1):117-128. doi: 10.1002/ana.24844.

30.

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.

Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, Mathis CA, Klunk WE, Chakrabarty A, Ironside J, Ismail A, Smith C, Thal DR, Beach TG, Farrar G, Smith AP.

Acta Neuropathol Commun. 2016 Dec 12;4(1):130.

31.

Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype.

Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, DeKosky ST, Klunk WE, Lopez OL.

JAMA Neurol. 2017 Jan 1;74(1):82-90. doi: 10.1001/jamaneurol.2016.3474.

32.

Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults.

Nadkarni NK, Lopez OL, Perera S, Studenski SA, Snitz BE, Erickson KI, Mathis CA, Nebes RD, Redfern M, Klunk WE.

J Gerontol A Biol Sci Med Sci. 2017 Mar 1;72(3):431-437. doi: 10.1093/gerona/glw211.

33.

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016.

34.

Tenascin-C Is Associated with Cored Amyloid-β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly.

Mi Z, Halfter W, Abrahamson EE, Klunk WE, Mathis CA, Mufson EJ, Ikonomovic MD.

J Neuropathol Exp Neurol. 2016 Sep;75(9):868-76. doi: 10.1093/jnen/nlw062. Epub 2016 Jul 21. Erratum in: J Neuropathol Exp Neurol. 2016 Dec;75(12):1190.

35.

[F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding.

Ikonomovic MD, Abrahamson EE, Price JC, Mathis CA, Klunk WE.

Ann Neurol. 2016 Aug;80(2):307-8. doi: 10.1002/ana.24706. Epub 2016 Jul 7. No abstract available.

36.

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.

Lingler JH, Butters MA, Gentry AL, Hu L, Hunsaker AE, Klunk WE, Mattos MK, Parker LS, Roberts JS, Schulz R.

J Alzheimers Dis. 2016 Mar 8;52(1):17-24. doi: 10.3233/JAD-150985. Erratum in: J Alzheimers Dis. 2017;56(3):1213.

37.

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Mar 24;11(3):e0152082. doi: 10.1371/journal.pone.0152082. eCollection 2016. Erratum in: PLoS One. 2016 Sep 20;11(9):e0163669.

38.

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.

Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.

Neuroimage Clin. 2015 Oct 14;9:592-8. doi: 10.1016/j.nicl.2015.10.007. eCollection 2015.

39.

Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities.

Goodheart AE, Tamburo E, Minhas D, Aizenstein HJ, McDade E, Snitz BE, Price JC, Mathis CA, Lopez OL, Klunk WE, Cohen AD.

Neuroimage Clin. 2015 Sep 29;9:479-83. doi: 10.1016/j.nicl.2015.09.009. eCollection 2015.

40.

Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study.

Snitz BE, Lopez OL, McDade E, Becker JT, Cohen AD, Price JC, Mathis CA, Klunk WE.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9. doi: 10.3233/JAD-150113.

41.

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T.

Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.

42.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

43.

A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.

Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer’s Network.

Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015.

44.

Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals.

Gregg NM, Kim AE, Gurol ME, Lopez OL, Aizenstein HJ, Price JC, Mathis CA, James JA, Snitz BE, Cohen AD, Kamboh MI, Minhas D, Weissfeld LA, Tamburo EL, Klunk WE.

JAMA Neurol. 2015 Sep;72(9):1021-8. doi: 10.1001/jamaneurol.2015.1359.

45.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.

46.

The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.

Lao PJ, Betthauser TJ, Hillmer AT, Price JC, Klunk WE, Mihaila I, Higgins AT, Bulova PD, Hartley SL, Hardison R, Tumuluru RV, Murali D, Mathis CA, Cohen AD, Barnhart TE, Devenny DA, Mailick MR, Johnson SC, Handen BL, Christian BT.

Alzheimers Dement. 2016 Apr;12(4):380-90. doi: 10.1016/j.jalz.2015.05.013. Epub 2015 Jun 13.

47.

More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk.

Rosenthal SL, Bamne MN, Wang X, Berman S, Snitz BE, Klunk WE, Sweet RA, Demirci FY, Lopez OL, Kamboh MI.

Neurobiol Aging. 2015 Aug;36(8):2443.e21-6. doi: 10.1016/j.neurobiolaging.2015.04.012. Epub 2015 Apr 25.

48.

Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC.

J Nucl Med. 2015 Aug;56(8):1199-205. doi: 10.2967/jnumed.114.152405. Epub 2015 Jun 4.

49.

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ.

JAMA. 2015 May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669.

50.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

Supplemental Content

Loading ...
Support Center